https://www.syncsci.com/journal/JPBR <p><a title="Registered Journal" href="https://www.reviewercredits.com/user/j-pharm-biopharm-res" target="_blank" rel="noopener"><img class="journalreviewercredits" src="/journal/public/site/images/jasongong/Logo_ReviewerCredits-journal.jpg" alt="ReviewerCredits" align="right"></a><strong>Journal of Pharmaceutical and Biopharmaceutical Research (JPBR)</strong> (ISSN:2630-533X)&nbsp; is an open access, continuously published, international, refereed&nbsp; journal. The aim of the journal is to provide the authors a timely and peer reviewed process for evaluation and publication of their manuscripts. All articles submitted to JPBR will undergo a rigorous double-blind peer review, and all published articles can be downloaded and read for free. JPBR will pay wide attention to the trends in related fields and insist on publishing original research work of highest quality.</p> <p><strong>JPBR</strong> publishes high quality original research work, reviews, and short communications in the following areas:<br><strong>Pharmaceutical Sciences:<br></strong>• Pharmaceutics<br> • Pharmacology and Toxicology<br> • Medicinal Chemistry<br> • Physical Pharmacy<br> • Pharmaceutical Analysis<br> • Chromatography and Hyphenated Techniques<br> • Pharmacognosy and Phytochemistry<br> • Nanotechnology for Pharmaceutical Drug Formulations<br><strong>Biopharmaceutical Sciences:</strong> <br> • Biochemistry<br> • Biotechnology<br> • Molecular Biology<br> • Immunology and Microbiology</p> en-US <p>Authors contributing to&nbsp;<em>Journal of Pharmaceutical and Biopharmaceutical Research</em>&nbsp;agree to publish their articles under the&nbsp;<a href="http://creativecommons.org/licenses/by-nc/4.0">Creative Commons Attribution-Noncommercial 4.0 International License</a>, allowing third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, that the work is not used for commercial purposes, and that in the event of reuse or distribution, the terms of this license are made clear.</p> snowy.wang@syncsci.com (Snowy Wang) editor@syncsci.com (Alan Tan) Wed, 19 Apr 2023 16:45:52 +0800 OJS 3.1.1.0 http://blogs.law.harvard.edu/tech/rss 60 https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.01.001 <p><strong>Background:</strong> Atherosclerosis (AS) is one of the leading causes of cardiovascular diseases. The traditional China herb pairs such as Huanglian-Gualou, Honghua-Taoren, and Suhexiang-Bingpian showed therapeutic effects on AS by clearing heat and resolving phlegm, invigorating blood and removing blood stasis, as well as aromatic resuscitation, respectively. However, the common and specific mechanisms of these pairs against the same disease are elusive.<br><strong>Objective:</strong> This study aimed to explore the molecular mechanisms of 3 herb pairs treating AS by network pharmacology, molecular modeling and mechanism experiments.<br><strong>Methods:</strong> The components and their corresponding targets of 3 herb pairs, as well as AS-related targets, were collected from multiple databases and literature. Then the protein-protein interaction network was built to identify the key components and targets associated with AS. The pathway enrichment analysis using KEGG was carried out for analyzing the common mechanisms of 3 herb pairs against AS. Finally, the binding modes of the key components and targets were analyzed by molecular docking and molecular dynamic simulation.<br><strong>Results:</strong> The PPI network indicated that the common targets of 3 herb pairs focused on four pathways, including regulated vascular shear stress, TNF, ARE-RAGE, and IL-17 pathways. The molecular docking analysis indicated that the key component quercetin showed highest docking score with PTGS2 in comparison to other targets. Molecular dynamics simulations revealed that quercetin stably anchored to the active pocket of PTGS2 by forming hydrogen bonds with Thr175, Asn351, and Trp356.<br><strong>Conclusion:</strong> The molecular mechanism of Huanglian-Gualou, Honghua-Taoren, and Suhexiang-Bingpian against AS was preliminarily expounded, and we wish to provide a theoretical instruction for clinical treatment of AS.</p> Minjun Wang ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.01.001 Wed, 19 Apr 2023 16:45:35 +0800